Reports
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States
Americas
Future Market Insights, Inc.
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States
MEA
Future Market Insights
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom
Asia Pacific
Future Market Insights
IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India
The global Parkinson's disease market is expected to be worth US$ 3.7 billion in the fiscal year 2023. From 2023 to 2033, the global market is expected to grow at a steady 5.1% CAGR, reaching a value of US$ 6.1 billion by the end of 2033.
Parkinson's disease is a disorder of the brain that results in the death of nerve cells in a particular region of the brain. It affects a person in many different ways, including stiffness, sadness, memory issues, problems with coordination and balance, blood pressure, and thinking. Despite the fact that the ailment cannot be cured, there are several treatment options, including surgery, medications, and other therapies.
The major treatment for Parkinson's is levodopa. Levodopa is frequently used with the drug carbidopa to combat its many negative effects, including nausea, vomiting, lower blood pressure, and restlessness. The size of the market for treatments for Parkinson's disease is expanding as a result of evolving environmental variables and genetic predisposition
The high prevalence of Parkinson's Condition (PD) in western nations, the growing senior population, who are all at high risk for acquiring the disease, and the robust pipeline of disease-modifying medicines are all expected to be key business drivers. The International Parkinson and Movement Disorder Society estimates that 9.4 million people will have PD globally in 2020. Additionally, about 1% of people over the age of 60 are affected by PD, and that percentage jumps to 5% for people over the age of 85.
Additionally, recent advances and strategic actions by large or minor market participants are growing in both local and international markets. This is yet another important feature that will amplify the industry under study. For instance, Israel-based Pharma Two B Ltd. announced in December 2021 that its Phase III double-blind, active-controlled study of P2B001 in early Parkinson's disease had successfully met its primary and important secondary endpoints. P2B001 was superior to each of its individual components as measured by the change in the total Unified Parkinson's Disease Rating Scale from baseline to week 12, which was the study's primary endpoint. P2B001 outperformed the pramipexole and rasagiline components, respectively, by 2.66 and 3.30 points, respectively (p=0.0018 and p=0.0001).
Attributes | Details |
---|---|
Expected Market Value (2023) | US$ 3.7 billion |
Projected Forecast Value (2033) | US$ 6.1 billion |
Global Growth Rate (2023 to 2033) | 5.1% |
CAGR of North America (2023) | 12.5% |
CAGR of APAC (2023 to 2033) | 12% |
Prominent Players in The Global Market |
|
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global Parkinson's disease market grew at a CAGR of 6.8% from 2018 to 2022, as per Future Market Insights, a provider of market research and competitive intelligence. The Covid-19 pandemic has had a significant effect on the market. The COVID-19 pandemic has relatively little of an impact on the world market for Parkinson's disease medications. The epidemic has had a direct influence on the supply and demand for Parkinson's medications, as well as on businesses and financial markets. It has also disturbed the distribution system.
The gradual increase in PD prevalence has opened the door for major pharmaceutical companies to pursue significant market expansion in this industry. For pharmaceutical firms, the availability of several dosage forms might enable product diversification, resulting in higher profitability. For the treatment of people with moderate-to-severe PD for whom oral medicines are no longer effective, NeuroDerm is developing ND0612.
Such factors are expected to boost the global sales of Parkinson's disease solutions. As a result, the global Parkinson's disease market is expected to forecast a CAGR of over 5.1% from 2023-2033.
Continuous technological advances and research in this domain to boost the demand
Over the course of the analysis period, it is projected that ongoing developments in the Parkinson's disease drug category will drive market expansion. A research collaboration deal aimed at the discovery of novel biomolecular pre-clinical drug candidates for Parkinson's disease was signed in January 2022 by Iktos, a South Korean company that specializes in artificial intelligence (AI) for novel therapeutic design, and Astrogen, a medical and research-oriented biotech company aimed at developing new and innovative medications for the treatment of intractable neurodegenerative disorders.
Additionally, in March 2022, OrganoTherapeutics, a developer of patented technology patient-specific organoids that recapitulate Parkinson's Disease (PD) pathology, and Vyant Bio, Inc., an innovative biotechnology company concentrated on reinventing drug development for complex neurodevelopmental and neurodegenerative abnormalities, entered into a joint collaboration to work toward speeding up drug discovery. Such factors are sure to propel the market for Parkinson's disease during the forecast period.
New product introductions in the worldwide market for Parkinson's disease therapy will help the industry develop to its full potential. For example, Adamas Pharmaceuticals, Inc. revealed subgroup analyses of Parkinson's disease patients receiving amantadine immediate release (IR) who are still suffering dyskinesia and are recruited in the long-term EASE LID 2 trial in February 2018.
The current phase 3 open-label research of GOCOVRITM (amantadine) extended-release capsule data reveals that motor applications increase by roughly 35%. This patient's tolerability and safety profile were found to be consistent, with no side effects. Furthermore, the majority of the big companies have an extensive therapeutic pipeline for Parkinson's disease treatment. Such developments are expected to accelerate the demand for Parkinson's disease during the forecast period.
Discovery of various alternative treatments to impede the global market
Alternative medical therapies will have a significant influence on the worldwide Parkinson's disease industry. Alternative treatment methods and alternative items will face fierce competition from companies producing the same medicine. This will make it difficult for the producer to expand and offer other products on the market for the same type of sickness.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
High prevalence among the aging population to boost the regional demand
North America is predicted to hold the dominant market share of 41% revenue share in 2023 and is the fastest-growing market for Parkinson's disease, with a dominant 12.1% CAGR from 2023 to 2033.
The factors that lead to regional expansion involve very prevalent Parkinson's disease groups. Furthermore, the high prevalence found in the aging population fuels the growth of the Parkinson's disease market in North America. In the United States, almost 1 Billion people have Parkinson's disease. According to Parkinson's Foundation figures, this amount is significantly more than the total number of persons diagnosed with multiple sclerosis as well as muscular dystrophy.
The overall direct and indirect expenses of Parkinson's disease, including treatment, social payments, and lost income, are estimated to be about US$ 52 billion per year in the United States alone. Furthermore, the Parkinson's Prevalence Project predicts that 930,000 persons in the United States will have Parkinson's disease (PD) by 2020. This figure is estimated to reach 1.2 Billion by the year 2030. Hence, there would be a lot of scope for North American manufacturers to develop in this market during the forecast period.
Large patient pool and more research and awareness programs to propel the sales
During the forecast period, the APAC market for Parkinson's disease is expected to garner a steady CAGR of 12%. But at the time, this market is presently acquiring 31% market share in the global Parkinson's disease market.
The emergence of a larger number of generic manufacturers as well as substantial market prospects for Parkinson's disease, notably in China, India, and Japan, will eventually drive the geographical expansion of the Asia-Pacific Parkinson's disease market.
The region is also seeing growth as a result of expanded product penetration, untapped potential, and the rising prevalence of Parkinson's disease in emerging nations. For example, UCB S.A. got an Import Drug License (IDL) from the China Food and Drug Administration (CFDA) in July 2022 to supply and distribute Neupro in China. Neupro is suggested as monotherapy in conjunction with levodopa for the treatment of people with early-stage idiopathic Parkinson's disease. Such developments are expected to accelerate the growth in the market from 2023 to 2033.
The Carbidopa-levodopa drug class segment will gain the dominant market share
Over the course of the forecast period, the Carbidopa-levodopa segment by drug class is anticipated to occupy a significant share of the global Parkinson's disease market. In 2023, this category is anticipated to dominate with a 32% revenue share.
The high incidence of these medications' prescriptions was thought to be the cause of this rise. According to the US Drug Use Statistics, 183,670 Parkinson's patients are expected to receive 527,540 prescriptions for carbidopa-levodopa in 2021.
Combinations of the drugs carbidopa along with levodopa are used to treat Parkinson's disease (PD) symptoms. It is the most effective drug for PD and is frequently used as a second line of therapy. It can be taken largely orally, for example, as immediate-release pills, controlled-release tablets, enteral solution, or extended-release capsules.
Additionally, the existence of pipeline candidates like LY03003 and an increase in the market for dopamine agonists are elements that are anticipated to favorably contribute to segmental growth. Such factors are expected to accelerate the growth prospects for Parkinson's disease from 2023 to 2033.
The adult segment will become more significant from 2023 to 2033
On the basis of the age type, the other dominant segment is the adult segment, which is expected to occupy a global market share of 21% from 2023 to 2033.
According to the journal article "Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson's Disease: Past, Present, and Future" released in February 2022, there are an estimated 6.1 Billion people worldwide who have Parkinson's disease. The prevalence rises with age, reaching from 1% to 3% in people over 65.
Additionally, UN research estimates that 727 Billion people worldwide would be 65 years of age or older in 2020. In addition, it is anticipated that by 2050, there will be twice as many people worldwide who are 80 years of age or older.
Additionally, according to figures released by the World Health Organization (WHO) in October 2021, 1 in 6 persons worldwide would be 60 years of age or older by the year 2030. Consequently, it is projected that there will be a demographic change as the world's geriatric population rises. The rise in older adults is anticipated to accelerate market growth over the study period.
The start-ups want to differentiate their products on the worldwide market by adding new technology and improved safety features to their products. They are first concentrating on reducing the symptoms. Some of the businesses include:
Some of the prominent players in the global market for Parkinson's disease are:
Some of the prominent developments of the key players in the market are:
Value-added Insights:
By Phase
By Drug Class
By Company
50 mg levodopa combined with 12.5 mg carbidopa
100 mg levodopa combined with 25 mg carbidopa
100 mg levodopa combined with 10 mg carbidopa
200 mg levodopa combined with 50 mg carbidopa
250 mg levodopa combined with 25 mg carbidopa
0.125 mg
0.25 mg
1.5 mg
5 mg
0.5 mg
1 mg
1.25 mg
2.5 mg
5 mg
10 mg
100 mg
200 mg
Oral Ordinary (immediate release, oral disintegrating, oral solution)
Oral Long Acting (extended release)
Pre-filled Syringes
Vials
Hospitals
Specialty Clinics
Others
Retail Pharmacies
Drug Stores
Online Pharmacy
During the historical period of 2018 to 2022, the Parkinson's disease market grew at a CAGR of 6.8%.
The global Parkinson's disease market is predicted to rise with a steady 5.1% CAGR from 2023 to 2033.
The global Parkinson's disease market is currently worth more than US$ 3.7 billion.
By 2033, the global Parkinson's disease market is projected to reach a market size of US$ 6.1 billion.
In 2023, the Carbidopa-levodopa segment by drug class type is anticipated to dominate with a 32% revenue share.
The adult segment by age type will occupy the second largest segment during the forecast period with a 21% market share in 2023.
The North American region is predicted to grow with a steady CAGR of 12.5% from 2023 to 2033.
The APAC Parkinson's disease market is expected to grow with a steady CAGR of 12% from 2023 to 2033.
1. Executive Summary | Parkinson's Disease Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033 5.3.1. Juvenile Parkinson's Disease 5.3.2. Young-onset Parkinson’s Disease 5.3.3. Idiopathic Parkinson's Disease 5.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Age 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Age, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Age, 2023 to 2033 6.3.1. Adult 6.3.2. Pediatric 6.4. Y-o-Y Growth Trend Analysis By Age, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Age, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Diagnosis 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Diagnosis, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Diagnosis, 2023 to 2033 7.3.1. CT Scan 7.3.2. MRI Scan 7.3.3. DaTSCAN-SPECT scan 7.3.4. PET Scan 7.4. Y-o-Y Growth Trend Analysis By Diagnosis, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Diagnosis, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 8.1. Introduction / Key Findings 8.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022 8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033 8.3.1. Carbidopa-levodopa 8.3.2. Carbidopa-levodopa infusion 8.3.3. Dopamine Agonists 8.3.4. Monoamine Oxidase B Inhibitors 8.3.5. Catechol O-methyltransferase Inhibitors 8.3.6. Anticholinergics 8.3.7. Amantadine 8.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022 8.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 9.1. Introduction 9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 9.3.1. North America 9.3.2. Latin America 9.3.3. Western Europe 9.3.4. Eastern Europe 9.3.5. Asia-Pacific 9.3.6. Middle East & Africa (MEA) 9.4. Market Attractiveness Analysis By Region 10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. The US 10.2.1.2. Canada 10.2.2. By Type 10.2.3. By Age 10.2.4. By Diagnosis 10.2.5. By Drug Class 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Type 10.3.3. By Age 10.3.4. By Diagnosis 10.3.5. By Drug Class 10.4. Key Takeaways 11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Brazil 11.2.1.2. Mexico 11.2.1.3. Rest of Latin America 11.2.2. By Type 11.2.3. By Age 11.2.4. By Diagnosis 11.2.5. By Drug Class 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Type 11.3.3. By Age 11.3.4. By Diagnosis 11.3.5. By Drug Class 11.4. Key Takeaways 12. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Benelux 12.2.1.2. France 12.2.1.3. Germany 12.2.1.4. Italy 12.2.1.5. Nordic 12.2.1.6. Spain 12.2.1.7. The UK 12.2.1.8. Rest of Western Europe 12.2.2. By Type 12.2.3. By Age 12.2.4. By Diagnosis 12.2.5. By Drug Class 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Type 12.3.3. By Age 12.3.4. By Diagnosis 12.3.5. By Drug Class 12.4. Key Takeaways 13. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. Poland 13.2.1.2. Russia 13.2.1.3. Rest of Eastern Europe 13.2.2. By Type 13.2.3. By Age 13.2.4. By Diagnosis 13.2.5. By Drug Class 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Type 13.3.3. By Age 13.3.4. By Diagnosis 13.3.5. By Drug Class 13.4. Key Takeaways 14. APAC Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. India 14.2.1.2. Malaysia 14.2.1.3. Singapore 14.2.1.4. Thailand 14.2.1.5. Australia 14.2.1.6. New Zealand 14.2.1.7. Rest of APAC 14.2.2. By Type 14.2.3. By Age 14.2.4. By Diagnosis 14.2.5. By Drug Class 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Type 14.3.3. By Age 14.3.4. By Diagnosis 14.3.5. By Drug Class 14.4. Key Takeaways 15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Type 15.2.3. By Age 15.2.4. By Diagnosis 15.2.5. By Drug Class 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Type 15.3.3. By Age 15.3.4. By Diagnosis 15.3.5. By Drug Class 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. The US 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2022 16.1.2.1. By Type 16.1.2.2. By Age 16.1.2.3. By Diagnosis 16.1.2.4. By Drug Class 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2022 16.2.2.1. By Type 16.2.2.2. By Age 16.2.2.3. By Diagnosis 16.2.2.4. By Drug Class 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2022 16.3.2.1. By Type 16.3.2.2. By Age 16.3.2.3. By Diagnosis 16.3.2.4. By Drug Class 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2022 16.4.2.1. By Type 16.4.2.2. By Age 16.4.2.3. By Diagnosis 16.4.2.4. By Drug Class 16.5. Benelux 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2022 16.5.2.1. By Type 16.5.2.2. By Age 16.5.2.3. By Diagnosis 16.5.2.4. By Drug Class 16.6. France 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2022 16.6.2.1. By Type 16.6.2.2. By Age 16.6.2.3. By Diagnosis 16.6.2.4. By Drug Class 16.7. Germany 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2022 16.7.2.1. By Type 16.7.2.2. By Age 16.7.2.3. By Diagnosis 16.7.2.4. By Drug Class 16.8. Italy 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2022 16.8.2.1. By Type 16.8.2.2. By Age 16.8.2.3. By Diagnosis 16.8.2.4. By Drug Class 16.9. Nordic 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2022 16.9.2.1. By Type 16.9.2.2. By Age 16.9.2.3. By Diagnosis 16.9.2.4. By Drug Class 16.10. Spain 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2022 16.10.2.1. By Type 16.10.2.2. By Age 16.10.2.3. By Diagnosis 16.10.2.4. By Drug Class 16.11. The UK 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2022 16.11.2.1. By Type 16.11.2.2. By Age 16.11.2.3. By Diagnosis 16.11.2.4. By Drug Class 16.12. Poland 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2022 16.12.2.1. By Type 16.12.2.2. By Age 16.12.2.3. By Diagnosis 16.12.2.4. By Drug Class 16.13. Russia 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2022 16.13.2.1. By Type 16.13.2.2. By Age 16.13.2.3. By Diagnosis 16.13.2.4. By Drug Class 16.14. India 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2022 16.14.2.1. By Type 16.14.2.2. By Age 16.14.2.3. By Diagnosis 16.14.2.4. By Drug Class 16.15. Malaysia 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2022 16.15.2.1. By Type 16.15.2.2. By Age 16.15.2.3. By Diagnosis 16.15.2.4. By Drug Class 16.16. Singapore 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2022 16.16.2.1. By Type 16.16.2.2. By Age 16.16.2.3. By Diagnosis 16.16.2.4. By Drug Class 16.17. Thailand 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2022 16.17.2.1. By Type 16.17.2.2. By Age 16.17.2.3. By Diagnosis 16.17.2.4. By Drug Class 16.18. Australia 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2022 16.18.2.1. By Type 16.18.2.2. By Age 16.18.2.3. By Diagnosis 16.18.2.4. By Drug Class 16.19. New Zealand 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2022 16.19.2.1. By Type 16.19.2.2. By Age 16.19.2.3. By Diagnosis 16.19.2.4. By Drug Class 16.20. GCC Countries 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2022 16.20.2.1. By Type 16.20.2.2. By Age 16.20.2.3. By Diagnosis 16.20.2.4. By Drug Class 16.21. South Africa 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2022 16.21.2.1. By Type 16.21.2.2. By Age 16.21.2.3. By Diagnosis 16.21.2.4. By Drug Class 16.22. Israel 16.22.1. Pricing Analysis 16.22.2. Market Share Analysis, 2022 16.22.2.1. By Type 16.22.2.2. By Age 16.22.2.3. By Diagnosis 16.22.2.4. By Drug Class 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Type 17.3.3. By Age 17.3.4. By Diagnosis 17.3.5. By Drug Class 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Sunovion Pharmaceuticals 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. Adamas Pharmaceuticals 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. Neurocrine Biosciences 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Supernus Pharmaceuticals 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Kyowa Kirin 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. AbbVie 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Integrative Research Laboratories AB 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Annovis Bio Inc. 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Cerevel Therapeutics 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. AMillioneal Pharmaceuticals 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033 Table 2: Global Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 3: Global Market Value (US$ Million) Forecast by Age, 2018 to 2033 Table 4: Global Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033 Table 5: Global Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 6: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 7: North America Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 8: North America Market Value (US$ Million) Forecast by Age, 2018 to 2033 Table 9: North America Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033 Table 10: North America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 11: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 12: Latin America Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 13: Latin America Market Value (US$ Million) Forecast by Age, 2018 to 2033 Table 14: Latin America Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033 Table 15: Latin America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 16: Western Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 17: Western Europe Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 18: Western Europe Market Value (US$ Million) Forecast by Age, 2018 to 2033 Table 19: Western Europe Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033 Table 20: Western Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 21: Eastern Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 22: Eastern Europe Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 23: Eastern Europe Market Value (US$ Million) Forecast by Age, 2018 to 2033 Table 24: Eastern Europe Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033 Table 25: Eastern Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 26: APAC Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 27: APAC Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 28: APAC Market Value (US$ Million) Forecast by Age, 2018 to 2033 Table 29: APAC Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033 Table 30: APAC Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 31: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 32: MEA Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 33: MEA Market Value (US$ Million) Forecast by Age, 2018 to 2033 Table 34: MEA Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033 Table 35: MEA Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Figure 1: Global Market Value (US$ Million) by Type, 2023 to 2033 Figure 2: Global Market Value (US$ Million) by Age, 2023 to 2033 Figure 3: Global Market Value (US$ Million) by Diagnosis, 2023 to 2033 Figure 4: Global Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 5: Global Market Value (US$ Million) by Region, 2023 to 2033 Figure 6: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033 Figure 7: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033 Figure 8: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033 Figure 9: Global Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 10: Global Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 11: Global Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 12: Global Market Value (US$ Million) Analysis by Age, 2018 to 2033 Figure 13: Global Market Value Share (%) and BPS Analysis by Age, 2023 to 2033 Figure 14: Global Market Y-o-Y Growth (%) Projections by Age, 2023 to 2033 Figure 15: Global Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033 Figure 16: Global Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033 Figure 17: Global Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033 Figure 18: Global Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 19: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 20: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 21: Global Market Attractiveness by Type, 2023 to 2033 Figure 22: Global Market Attractiveness by Age, 2023 to 2033 Figure 23: Global Market Attractiveness by Diagnosis, 2023 to 2033 Figure 24: Global Market Attractiveness by Drug Class, 2023 to 2033 Figure 25: Global Market Attractiveness by Region, 2023 to 2033 Figure 26: North America Market Value (US$ Million) by Type, 2023 to 2033 Figure 27: North America Market Value (US$ Million) by Age, 2023 to 2033 Figure 28: North America Market Value (US$ Million) by Diagnosis, 2023 to 2033 Figure 29: North America Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 30: North America Market Value (US$ Million) by Country, 2023 to 2033 Figure 31: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 32: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 33: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 34: North America Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 35: North America Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 36: North America Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 37: North America Market Value (US$ Million) Analysis by Age, 2018 to 2033 Figure 38: North America Market Value Share (%) and BPS Analysis by Age, 2023 to 2033 Figure 39: North America Market Y-o-Y Growth (%) Projections by Age, 2023 to 2033 Figure 40: North America Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033 Figure 41: North America Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033 Figure 42: North America Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033 Figure 43: North America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 44: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 45: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 46: North America Market Attractiveness by Type, 2023 to 2033 Figure 47: North America Market Attractiveness by Age, 2023 to 2033 Figure 48: North America Market Attractiveness by Diagnosis, 2023 to 2033 Figure 49: North America Market Attractiveness by Drug Class, 2023 to 2033 Figure 50: North America Market Attractiveness by Country, 2023 to 2033 Figure 51: Latin America Market Value (US$ Million) by Type, 2023 to 2033 Figure 52: Latin America Market Value (US$ Million) by Age, 2023 to 2033 Figure 53: Latin America Market Value (US$ Million) by Diagnosis, 2023 to 2033 Figure 54: Latin America Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 55: Latin America Market Value (US$ Million) by Country, 2023 to 2033 Figure 56: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 57: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 58: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 59: Latin America Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 60: Latin America Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 61: Latin America Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 62: Latin America Market Value (US$ Million) Analysis by Age, 2018 to 2033 Figure 63: Latin America Market Value Share (%) and BPS Analysis by Age, 2023 to 2033 Figure 64: Latin America Market Y-o-Y Growth (%) Projections by Age, 2023 to 2033 Figure 65: Latin America Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033 Figure 66: Latin America Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033 Figure 67: Latin America Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033 Figure 68: Latin America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 69: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 70: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 71: Latin America Market Attractiveness by Type, 2023 to 2033 Figure 72: Latin America Market Attractiveness by Age, 2023 to 2033 Figure 73: Latin America Market Attractiveness by Diagnosis, 2023 to 2033 Figure 74: Latin America Market Attractiveness by Drug Class, 2023 to 2033 Figure 75: Latin America Market Attractiveness by Country, 2023 to 2033 Figure 76: Western Europe Market Value (US$ Million) by Type, 2023 to 2033 Figure 77: Western Europe Market Value (US$ Million) by Age, 2023 to 2033 Figure 78: Western Europe Market Value (US$ Million) by Diagnosis, 2023 to 2033 Figure 79: Western Europe Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 80: Western Europe Market Value (US$ Million) by Country, 2023 to 2033 Figure 81: Western Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 82: Western Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 83: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 84: Western Europe Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 85: Western Europe Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 86: Western Europe Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 87: Western Europe Market Value (US$ Million) Analysis by Age, 2018 to 2033 Figure 88: Western Europe Market Value Share (%) and BPS Analysis by Age, 2023 to 2033 Figure 89: Western Europe Market Y-o-Y Growth (%) Projections by Age, 2023 to 2033 Figure 90: Western Europe Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033 Figure 91: Western Europe Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033 Figure 92: Western Europe Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033 Figure 93: Western Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 94: Western Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 95: Western Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 96: Western Europe Market Attractiveness by Type, 2023 to 2033 Figure 97: Western Europe Market Attractiveness by Age, 2023 to 2033 Figure 98: Western Europe Market Attractiveness by Diagnosis, 2023 to 2033 Figure 99: Western Europe Market Attractiveness by Drug Class, 2023 to 2033 Figure 100: Western Europe Market Attractiveness by Country, 2023 to 2033 Figure 101: Eastern Europe Market Value (US$ Million) by Type, 2023 to 2033 Figure 102: Eastern Europe Market Value (US$ Million) by Age, 2023 to 2033 Figure 103: Eastern Europe Market Value (US$ Million) by Diagnosis, 2023 to 2033 Figure 104: Eastern Europe Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 105: Eastern Europe Market Value (US$ Million) by Country, 2023 to 2033 Figure 106: Eastern Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 107: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 108: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 109: Eastern Europe Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 110: Eastern Europe Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 111: Eastern Europe Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 112: Eastern Europe Market Value (US$ Million) Analysis by Age, 2018 to 2033 Figure 113: Eastern Europe Market Value Share (%) and BPS Analysis by Age, 2023 to 2033 Figure 114: Eastern Europe Market Y-o-Y Growth (%) Projections by Age, 2023 to 2033 Figure 115: Eastern Europe Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033 Figure 116: Eastern Europe Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033 Figure 117: Eastern Europe Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033 Figure 118: Eastern Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 119: Eastern Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 120: Eastern Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 121: Eastern Europe Market Attractiveness by Type, 2023 to 2033 Figure 122: Eastern Europe Market Attractiveness by Age, 2023 to 2033 Figure 123: Eastern Europe Market Attractiveness by Diagnosis, 2023 to 2033 Figure 124: Eastern Europe Market Attractiveness by Drug Class, 2023 to 2033 Figure 125: Eastern Europe Market Attractiveness by Country, 2023 to 2033 Figure 126: APAC Market Value (US$ Million) by Type, 2023 to 2033 Figure 127: APAC Market Value (US$ Million) by Age, 2023 to 2033 Figure 128: APAC Market Value (US$ Million) by Diagnosis, 2023 to 2033 Figure 129: APAC Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 130: APAC Market Value (US$ Million) by Country, 2023 to 2033 Figure 131: APAC Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 132: APAC Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 133: APAC Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 134: APAC Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 135: APAC Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 136: APAC Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 137: APAC Market Value (US$ Million) Analysis by Age, 2018 to 2033 Figure 138: APAC Market Value Share (%) and BPS Analysis by Age, 2023 to 2033 Figure 139: APAC Market Y-o-Y Growth (%) Projections by Age, 2023 to 2033 Figure 140: APAC Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033 Figure 141: APAC Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033 Figure 142: APAC Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033 Figure 143: APAC Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 144: APAC Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 145: APAC Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 146: APAC Market Attractiveness by Type, 2023 to 2033 Figure 147: APAC Market Attractiveness by Age, 2023 to 2033 Figure 148: APAC Market Attractiveness by Diagnosis, 2023 to 2033 Figure 149: APAC Market Attractiveness by Drug Class, 2023 to 2033 Figure 150: APAC Market Attractiveness by Country, 2023 to 2033 Figure 151: MEA Market Value (US$ Million) by Type, 2023 to 2033 Figure 152: MEA Market Value (US$ Million) by Age, 2023 to 2033 Figure 153: MEA Market Value (US$ Million) by Diagnosis, 2023 to 2033 Figure 154: MEA Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 155: MEA Market Value (US$ Million) by Country, 2023 to 2033 Figure 156: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 157: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 158: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 159: MEA Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 160: MEA Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 161: MEA Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 162: MEA Market Value (US$ Million) Analysis by Age, 2018 to 2033 Figure 163: MEA Market Value Share (%) and BPS Analysis by Age, 2023 to 2033 Figure 164: MEA Market Y-o-Y Growth (%) Projections by Age, 2023 to 2033 Figure 165: MEA Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033 Figure 166: MEA Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033 Figure 167: MEA Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033 Figure 168: MEA Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 169: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 170: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 171: MEA Market Attractiveness by Type, 2023 to 2033 Figure 172: MEA Market Attractiveness by Age, 2023 to 2033 Figure 173: MEA Market Attractiveness by Diagnosis, 2023 to 2033 Figure 174: MEA Market Attractiveness by Drug Class, 2023 to 2033 Figure 175: MEA Market Attractiveness by Country, 2023 to 2033
Recommendations
Explore Healthcare Insights
View Reports